Evidence map›Paper›PMID 40362304›Full record

ReviewInternational journal of molecular sciences2025

Targets and Gene Therapy of ALS (Part 1).

Olga Shiryaeva, Christina Tolochko, Tatiana Alekseeva, Vyacheslav Dyachuk

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. G-Quadruplexes Abet Neuronal Burnout in ALS and FTD.Antioxidants (Basel, Switzerland) · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Olga ShiryaevaAlmazov Federal Medical Research Centre, 197341 Saint Petersburg, Russia.
Christina TolochkoAlmazov Federal Medical Research Centre, 197341 Saint Petersburg, Russia.ORCID 0009-0001-8172-5374
Tatiana AlekseevaAlmazov Federal Medical Research Centre, 197341 Saint Petersburg, Russia.
Vyacheslav DyachukAlmazov Federal Medical Research Centre, 197341 Saint Petersburg, Russia.ORCID 0000-0001-8100-7367

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the selective death of motor neurons, which causes muscle atrophy. Genetic forms of ALS are recorded only in 10% of cases. However, over the past decade, studies in genetics have substantially contributed to our understanding of the molecular mechanisms underlying ALS. The identification of key mutations such as

Indexed as

Amyotrophic Lateral SclerosisGenetic TherapyAnimalsC9orf72 ProteinCRISPR-Cas SystemsDisease Models, AnimalDNA-Binding ProteinsGene EditingHumansMicroRNAsMotor NeuronsMutationOligonucleotides, AntisenseRNA-Binding Protein FUSRNA InterferenceRNA, Small InterferingC9orf72 ProteinC9orf72 protein, humanDNA-Binding ProteinsMicroRNAsOligonucleotides, AntisenseRNA-Binding Protein FUSRNA, Small InterferingSOD1 protein, humanSuperoxide Dismutase-1TARDBP protein, humanALS pathogenesisantisense oligonucleotides (ASO)C9orf72CRISPR/Cas9FUSgene therapy of ALSRNA interferenceSOD1TARDBP

Identifiers

PMID40362304
PMCPMC12071412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.